See the PATTRns | Homepage

Transthyretin amyloidosis (ATTR amyloidosis) is a systemic, progressive, and potentially fatal disease that may affect multiple organ systems and is frequently under-recognised due to its non-specific and heterogeneous manifestations^1–3

TAKE ACTION.

Early suspicion of ATTR amyloidosis may enable more timely diagnosis and management^1,4-6

If you suspect ATTR amyloidosis, it is important to refer your patients to the National Amyloidosis Centre to be assessed

It is important to suspect ATTR amyloidosis signs and symptoms to facilitate earlier diagnosis and treatment¹

Recognise the signs and symptoms of ATTR amyloidosis

SEE THE SIGNS AND SYMPTOMS

Misdiagnosis or delayed diagnosis of ATTR amyloidosis may contribute to disease progression and worsening of quality of life, including progression of polyneuropathic and cardiac manifestations^1,2,4

Early diagnosis and appropriate referral are important

DISCOVER DIAGNOSTIC TOOLS

ATTR=transthyretin amyloidosis.

References: 1. Nativi-Nicolau JN, et al. Heart Fail Rev. 2022;27(3):785–793; 2. Adams D et al. J Neurol. 2021;268(6):2109–2122; 3. Gertz MA, et al. BMC Fam Pract. 2020;21(1):198;  4. Rozenbaum MH, et al. J Comp Eff Res. 2021;10(11):927–938. 5. Gonzàlez-Duarte, et al. Neuro Ther. 2020;9:135–149; 6. Keohane D, et al. Amyloid. 2017;24(1):30–36.

GB-77258 | September 2026